ABBVIE

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 2013-01-01

Employees: -

Market Cap: $346B

Website: http://www.abbvie.com

Clinical Trials

Comparison of Bimatoprost Sustained Release (SR) to Selective Laser Trabeculoplasty (SLT) in Adults With Open-Angle Glaucoma or Ocular Hypertension

Phase 3

Completed

Conditions: Glaucoma, Open-Angle
Ocular Hypertension

Interventions: Drug: Bimatoprost SR
Drug: Sham Bimatoprost SR
Procedure: Selective Laser Trabeculoplasty
Procedure: Sham Selective Laser Trabeculoplasty

First Posted Date: 2015-07-24

Last Posted Date: 2024-05-10

Lead Sponsor: AbbVie

Target Recruit Count: 240

Registration Number: NCT02507687

Locations: 🇺🇸
Wolstan & Goldberg Eye Associates /ID# 235166, Torrance, California, United States
🇺🇸
Trinity Research Group /ID# 234598, Dothan, Alabama, United States
🇺🇸
Houston Eye Associates /ID# 237883, Houston, Texas, United States

and more 92 locations

Impact of Adalimumab on Patient-reported Outcomes in Ulcerative Colitis

Completed

Conditions: Ulcerative Colitis

First Posted Date: 2015-07-23

Last Posted Date: 2021-01-25

Lead Sponsor: AbbVie

Target Recruit Count: 100

Registration Number: NCT02506179

Locations: 🇨🇦
Bellini Medicine Professional /ID# 144241, Brampton, Ontario, Canada
🇨🇦
Oshawa Clinic /ID# 144364, Oshawa, Ontario, Canada
🇨🇦
The Ottawa Hospital /ID# 139392, Ottawa, Ontario, Canada

and more 20 locations

A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/r With or Without Dasabuvir and With or Without Ribavirin in Chronic Hepatitis C Virus Genotype 1 or 4 Infected Adults With Successfully Treated Early Stage Hepatocellular Carcinoma

Phase 3

Terminated

Conditions: Chronic Hepatitis C Infection

Interventions: Drug: ombitasvir/paritaprevir/ritonavir and dasabuvir
Drug: ombitasvir/paritaprevir/ritonavir
Drug: ribavirin

First Posted Date: 2015-07-21

Last Posted Date: 2017-12-12

Lead Sponsor: AbbVie

Target Recruit Count: 3

Registration Number: NCT02504099

A Prospective Non-interventional Multicenter Study to Evaluate the Effectiveness of Adalimumab in Korean Patients With Ulcerative Colitis (UC) and Identify Potential Predictors of Clinical Response in Routine Clinical Practice

Completed

Conditions: Ulcerative Colitis

First Posted Date: 2015-07-16

Last Posted Date: 2019-11-01

Lead Sponsor: AbbVie

Target Recruit Count: 150

Registration Number: NCT02499263

Locations: 🇰🇷
Korea University Anam Hospital /ID# 138446, Seoul, Korea, Republic of
🇰🇷
Kyungpook National Univ Hosp /ID# 153133, Daegu, Daegu Gwang Yeogsi, Korea, Republic of
🇰🇷
St. Vincent's Hospital /ID# 138455, Suwon, Gyeonggido, Korea, Republic of

and more 16 locations

Study to Evaluate the Safety and Efficacy of Adalimumab in Chinese Subjects With Moderate to Severe Crohn's Disease

Phase 3

Completed

Conditions: Crohn's Disease

Interventions: Biological: adalimumab
Other: placebo

First Posted Date: 2015-07-16

Last Posted Date: 2019-01-04

Lead Sponsor: AbbVie

Target Recruit Count: 205

Registration Number: NCT02499783

Ombitasvir/ABT-450/Ritonavir and Dasabuvir Therapy With Low Dose Ribavirin (RBV), Full Dose RBV or RBV Add-On in Treatment Naive Genotype 1a Hepatitis C Virus Infected Adults

Phase 2

Completed

Conditions: Hepatitis C (HCV)
Hepatitis C Genotype 1a
Chronic Hepatitis C

Interventions: Drug: Ombitasvir/ABT-450/Ritonavir
Drug: Dasabuvir
Drug: Ribavirin (RBV)

First Posted Date: 2015-07-10

Last Posted Date: 2017-10-31

Lead Sponsor: AbbVie

Target Recruit Count: 46

Registration Number: NCT02493855

A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects

Phase 2

Completed

Conditions: Chronic Hepatitis C Infection

Interventions: Drug: Ombitasvir mini tablet
Drug: Ombitasvir/paritaprevir/ritonavir
Drug: Paritaprevir mini tablet
Drug: Dasabuvir
Drug: Ritonavir mini tablet
Drug: Ribavirin
Drug: Dasabuvir mini tablet
Drug: Ribavirin solution

First Posted Date: 2015-07-01

Last Posted Date: 2021-10-05

Lead Sponsor: AbbVie

Target Recruit Count: 64

Registration Number: NCT02486406

Locations: 🇵🇷
San Jorge Children Hospital /ID# 136832, San Juan, Puerto Rico
🇺🇸
Seattle Children's Hospital /ID# 137019, Seattle, Washington, United States
🇩🇪
Helios Klinikum Wuppertal /ID# 142883, Wuppertal, Germany

and more 18 locations

Ombitasvir/Paritaprevir/Ritonavir With or Without Dasabuvir in Adults With Genotype 1a or Genotype 4 Chronic Hepatitis C Virus (HCV) Infection, With Severe Kidney Impairment or End Stage Kidney Disease

Phase 3

Completed

Conditions: Hepatitis C Virus (HCV)

Interventions: Drug: ombitasvir/paritaprevir/ritonavir and dasabuvir
Drug: ombitasvir/paritaprevir/ritonavir

First Posted Date: 2015-07-01

Last Posted Date: 2017-12-04

Lead Sponsor: AbbVie

Target Recruit Count: 18

Registration Number: NCT02487199

Observational Study Evaluating Long-term Health Outcomes of Canadian DUODOPA-treated Patients

Completed

Conditions: Parkinson Disease (PD)

First Posted Date: 2015-06-30

Last Posted Date: 2021-06-25

Lead Sponsor: AbbVie

Target Recruit Count: 88

Registration Number: NCT02485600

Locations: 🇨🇦
Hamilton Health Sciences /ID# 148808, Hamilton, Ontario, Canada
🇨🇦
St. Boniface Clinic, CA /ID# 162092, Winnipeg, Manitoba, Canada
🇨🇦
Kingston General Hospital /ID# 144942, Kingston, Ontario, Canada

and more 10 locations

Veliparib in Combination With Carboplatin And Weekly Paclitaxel in Japanese Subjects With Ovarian Cancer

Phase 1

Completed

Conditions: Ovarian Cancer

Interventions: Drug: veliparib
Drug: carboplatin
Drug: paclitaxel

First Posted Date: 2015-06-26

Last Posted Date: 2017-11-20

Lead Sponsor: AbbVie

Target Recruit Count: 9

Registration Number: NCT02483104

Locations: 🇯🇵
Site Reference ID/Investigator# 128815, Kurume-shi,Fukuoka, Japan
🇯🇵
Site Reference ID/Investigator# 128058, Nagaizumi-cho, Japan
🇯🇵
Site Reference ID/Investigator# 128997, Morioka-shi, Japan

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy